Cerebral cavernous malformations (CCMs) are common inherited and sporadic vascular malformations that cause strokes and seizures in younger individuals 1 . CCMs arise from endothelial cell loss of KRIT1, CCM2 or PDCD10, non-homologous proteins that form an adaptor complex 2 . How disruption of the CCM complex results in disease remains controversial, with numerous signalling pathways (including Rho 3,4 , SMAD 5 and Wnt/β-catenin 6 ) and processes such as endothelial-mesenchymal transition (EndMT) 5 proposed to have causal roles. CCM2 binds to MEKK3 (refs 7-11), and we have recently shown that CCM complex regulation of MEKK3 is essential during vertebrate heart development 12 . Here we investigate this mechanism in CCM disease pathogenesis. Using a neonatal mouse model of CCM disease, we show that expression of the MEKK3 target genes Klf2 and Klf4, as well as Rho and ADAMTS protease activity, are increased in the endothelial cells of early CCM lesions. By contrast, we find no evidence of EndMT or increased SMAD or Wnt signalling during early CCM formation. Endothelial-specific loss of Map3k3 (also known as Mekk3), Klf2 or Klf4 markedly prevents lesion formation, reverses the increase in Rho activity, and rescues lethality. Consistent with these findings in mice, we show that endothelial expression of KLF2 and KLF4 is increased in human familial and sporadic CCM lesions, and that a disease-causing human CCM2 mutation abrogates the MEKK3 interaction without affecting CCM complex formation. These studies identify gain of MEKK3 signalling and KLF2/4 function as causal mechanisms for CCM pathogenesis that may be targeted to develop new CCM therapeutics.
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We recently demonstrated that loss of KRIT1, CCM2 or PDCD10 in endothelial cells of the developing mouse heart upregulates expression of KLF2, KLF4, ADAMTS4 and ADAMTS5 owing to increased activity of the MEKK3 signalling pathway 12 . Analysis of isolated cerebellar endothelial cells from neonatal Krit1 ECKO and littermate control mice at P6 revealed increased Adamts4, but not Adamts5, messenger RNA and protein, in addition to increased levels of both Klf2 and Klf4 (Fig. 1d, f) . ADAMTS4 cleaves the proteoglycan versican to expose a neo-epitope (DPEAAE) that was detected immediately adjacent to the endothelial cells of both early and late CCM lesions ( Fig. 1e ). Increased levels of nuclear KLF4 protein and Klf2 mRNA were also detected in the endothelial cells of CCM lesions and other vessels in the cerebellum (Fig. 1e , g). These findings reveal increased levels of KLF2, KLF4 and ADAMTS4 during the earliest phase of CCM lesion formation in vivo.
Recent studies have implicated numerous signalling mechanisms as causal for CCM formation, including the Rho 3,4,14 , TGF-β/BMP 5 , Wnt/β-catenin 6 and Notch 15 pathways. To determine whether changes in Rho activity are an early event in CCM pathogenesis, we examined the ROCK substrate phosphorylated-myosin light chain (pMLC). pMLC levels were markedly increased in the brain capillary and venous endothelial cells of P6 neonatal Krit1 ECKO mice compared with littermate controls, including those lining the earliest detectable CCM lesions (Extended Data Fig. 2a ). TGF-β/BMP signalling through SMAD1 and SMAD3 and a mechanism of EndMT has been proposed to explain gene expression changes in KRIT1-deficient brain endothelial cells, including increased KLF4 (refs 5, 16) . A recent study by the same group suggested that increased β-catenin signalling is a primary event that culminates in later EndMT 6 . To assess endothelial β-catenin Letter reSeArCH signalling during CCM lesion formation, we generated neonatal Krit1 ECKO mice on a TCF/Lef:H2B-GFP Wnt/β-catenin reporter background 17 . Immunostaining for green fluorescent protein (GFP) revealed β-catenin signalling in white matter vascular endothelium that was not increased in P6 CCM lesions (Extended Data Fig. 2b ), while the levels of both GFP protein and the β-catenin target genes Axin2 and Lef1 were unchanged in cerebellar endothelial cells isolated from P6 or P11 neonatal Krit1 ECKO mice (Extended Data Fig. 2c, d ). Immunostaining of brain sections and immunoblotting of cerebellar endothelial cell protein also revealed no changes in pSMAD3 (Extended Data Fig. 2e , f). Finally, analysis of cerebellar endothelial gene expression analysis revealed no change in the expression of Notch target genes at P6, although an increase in Hes1 was noted at P11 (Extended Data Fig. 3 ). These studies reveal that primary CCM lesion formation is associated with increases in Klf2, Klf4 and Adamts4 expression and Rho/ ROCK activity, but not in TGF-β/BMP, Wnt/β-catenin or Notch signalling.
The above findings suggested that changes in KLF2/4 and ADAMTS4 expression may be causal for CCM formation. The CCM complex directly binds MEKK3 (refs 7-11), a MAP3 kinase known to regulate KLF2 and KLF4 expression in the embryonic heart in cultured endothelial cells 12 , and we previously found that Map3k3 haplo insufficiency rescues the loss of cardiac jelly associated with endocardial loss of CCM signalling 12 . Map3k3 haploinsufficiency was also found to rescue the early embryonic lethality conferred by panendothelial loss of KRIT1 (Extended Data Fig. 4a and ref. 18 ), suggesting that excess endothelial MEKK3 signalling may have a broad role in the cardiovascular phenotypes associated with loss of CCM signalling.
To determine whether this model underlies CCM formation, we generated iECre;Krit1 fl/fl ;Map3k3 fl/+ mice (termed Map3k3 HetRSQ mice). Visual inspection of the hindbrains of P11 Map3k3 HetRSQ mice compared with neonatal Krit1 ECKO littermate controls revealed a notable reduction in the number and size of vascular lesions ( Fig. 2a ). To quantify CCM formation, we imaged P11 hindbrains using contrast-enhanced, high resolution X-ray micro-computed tomography (microCT), and measured actual lesion volumes using semi-automated software. Map3k3 HetRSQ mouse hindbrains exhibited nearly complete prevention of the lesion phenotype compared with neonatal Krit1 ECKO littermates, as assessed by hindbrain microCT imaging ( Fig. 2b) , blinded measurement of total CCM lesion volume (Fig. 2c ), and measurements of Klf2, Klf4 and Adamts4 in P6 cerebellar endothelial cells (Fig. 2d ). While almost all neonatal Krit1 ECKO mice were dead by P30, all Map3k3 HetRSQ animals remained alive (Fig. 2e) , and exhibited normal growth and development. Finally, partial loss of MEKK3 also fully rescued CCM lesion formation in Ccm2 ECKO (iECre;Ccm2 fl/fl ) mice (Extended Data Fig. 4b ). These genetic findings support the conclusion that CCM lesions arise from gain of MEKK3 signalling and altered downstream gene expression in the endothelium.
Increased endothelial pMLC is coincident with increased Klf2, Klf4 and Adamts4 expression in the earliest CCM lesions (Fig. 1e, g and Extended Data Fig. 2a ), suggesting either that changes in Rho/ROCK activity are downstream of changes in MEKK3 activity or vice versa. The Rho-inhibiting agents hydroxyfasudil, tempol and vitamin D3 (ref. 19) failed to reverse the increase in KLF2 and KLF4 expression conferred by loss of KRIT1 in cultured human endothelial cells ( Fig. 2f ), suggesting that Rho is not upstream of the KLF2/4 expression changes associated with loss of CCM function. By contrast, P6 Map3k3 HetRSQ mice exhibited a complete normalization of endothelial pMLC staining (Fig. 2g) , indicating that increased Rho activity arises secondary to increased MEKK3 signalling during CCM formation.
To test the roles of KLF2 and KLF4 in CCM pathogenesis, we measured lesion formation in Fig. 3a-d) . Remarkably, Klf2 HomoRSQ mice exhibited 99% rescue (Fig. 3a, c) , with only a small amount of venule dilatation visible histologically (Extended Data Fig. 5 ). pMLC staining was normalized in P6 Klf2 HetRSQ mice (Fig. 3e) , indicating that increased Rho/ROCK activity arises secondary to increased KLF2 expression. These findings identify gain of KLF2 and KLF4 function as causal for CCM formation, and suggest that these transcription factors are the primary downstream targets of MEKK3 in this disease model. They also highlight the notable molecular conservation of this endothelial pathway: from zebrafish to mammals, and from embryonic vascular endothelium and endocardium to postnatal brain endothelium.
To determine whether MEKK3-KLF2/4 signalling is increased in human CCMs, we examined resected lesions from two patients with familial CCM bearing KRIT1 and PDCD10 germline mutations, and two sporadic CCM patients lacking any previous genetic or molecular data. Markedly increased nuclear KLF2 and KLF4 expression was observed in the endothelial cells of both familial and sporadic human CCM lesions (Fig. 4a, b) , consistent with increased MEKK3 signalling and studies performed using the mouse model. MEKK3 binds CCM2 through the carboxy-terminal helical harmonin domain of CCM2, and CCM2 truncation mutants lacking this domain do not bind MEKK3 (Extended Data Fig. 6a, b and refs 10, 11, 20, 21) . A literature search identified a familial CCM patient with a fournucleotide duplication in the last exon of CCM2 (CCCTdup) predicted to delete most of the helical harmonin domain 22 (Fig. 4c ). CCM2 CCCTdup expressed normally in HEK293T cells and bound KRIT1 and PDCD10 in a manner indistinguishable from wild-type CCM2, but failed to interact with MEKK3 ( Fig. 4c-e and Extended Data Fig. 6c ). These results suggest that specific disruption of the CCM2-MEKK3 interaction is sufficient to cause familial CCM Letter reSeArCH disease, and that human CCMs also arise due to loss of MEKK3 regulation and increased expression of KLF2 and KLF4.
How gain of MEKK3-KLF2/4 signalling confers CCM formation is unclear. It has been proposed that EndMT underlies CCM pathogenesis 5,6,23 , but we detect no evidence of a change in phenotype from endothelial to mesenchymal with loss of CCM signalling, and demonstrate that the loss of the non-mesenchymal transcription factor KLF2 is sufficient to rescue CCM formation fully. Our studies identify two effector pathways downstream of MEKK3-KLF2/4 signalling that may drive early CCM pathogenesis: Rho signalling and ADAMTS proteolytic activity. Increased Rho activity has been linked to increased stress fibre formation, loosened junctions and decreased tube formation in cultured endothelial cells 3, 14, 24 , and loss of vascular integrity in mice 4, 25 , but whether and how these changes might cause CCM formation is not yet clear. Increased ADAMTS activity is conferred by gain of KLF2 and KLF4 function (Extended Data Fig. 7) , and may confer CCM formation through breakdown of a proteoglycan matrix that is required specifically for the CNS vasculature (for example, versican; Extended Data Fig.  1b) . A proteolytic mechanism would also explain the autosomal dominant inheritance of this disease, as CCM-deficient endothelial cells generated by a rare second-hit mechanism 26, 27 could degrade the matrix supporting an entire vessel, thereby creating a cavernous malformation.
Finally, these studies may help to identify new therapies for CCM disease. Since MEKK3 upregulates KLF2 and KLF4 through the MEK5 and ERK5 downstream MAPKs 12,28 , we evaluated the effects of available inhibitors on CCM formation. BIX02189 (anti-MEK5) and XMD17-109 (anti-ERK5) reversed the increase in KLF2 and KLF4 expression associated with loss of CCM signalling in cultured endothelial cells (Extended Data Fig. 8 ), but failed to affect CCM formation at the low doses tolerated by neonatal Krit1 ECKO mice (not shown).
Therapies targeting Rho (for example, fasudil 29 or other recently identified agents 19 ) or the ADAMTS proteases may prove more effective, but future studies that rigorously test the causal role of these putative downstream effectors remain essential for the rational development of CCM disease therapies.
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